(update with more details)
The European Medicines Agency’s expert committee CHMP has published several new recommendations for various medicines, including Eli Lilly’s Foundayo (orforglipron), an oral GLP-1 receptor agonist for weight management and the treatment of type 2 diabetes in adults. The medicine is taken as one tablet once daily and, upon approval, will become an alternative to injectable and other oral GLP-1 medicines.
The European Commission will now review the positive opinion before Foundayo can receive approval. Competitor Novo Nordisk had its Wegovy pill approved in the EU in July. Foundayo was launched in the US in April, followed by the United Kingdom in August.
CHMP also recommended expanded treatment indications for five medicines that are already approved in the EU.
This concerned Novo Nordisk’s Kyinsu, Astra Zeneca’s pandemic influenza vaccine H5N1, Sobi’s Tryngolza and Pfizer’s Tukysa.
Sobi has separately commented on the positive opinion for Tryngolza.
“CHMP’s positive opinion reflects the strength of the clinical evidence and takes us one step closer to being able to offer Tryngolza as a new treatment option to reduce the risk of acute pancreatitis in patients with sHTG in the EU,” says Lydia Abad-Franch, MD, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi.
As with the other positive recommendations, final decisions from the European Commission are now awaited.